| Business Summary | | E.
I.
Du
Pont
De
Nemours
and
Company
is
engaged
in
science
and
technology
in
a
range
of
disciplines
including
high-performance
materials,
specialty
chemicals,
pharmaceuticals
and
biotechnology.
The
Company
operates
globally
through
some
20
strategic
business
units.
Within
the
strategic
business
units,
approximately
90
businesses
manufacture
and
sell
a
wide
range
of
products
to
many
different
markets,
including
the
transportation,
textile,
construction,
automotive,
agricultural
and
hybrid
seeds,
nutrition
and
health,
pharmaceuticals,
packaging
and
electronics
markets.
The
Company's
strategic
business
units
are
aggregated
into
nine
business
segments.
They
consist
of
Agriculture
&
Nutrition,
Nylon
Enterprise,
Performance
Coatings
&
Polymers,
Pharmaceuticals,
Pigments
&
Chemicals,
Pioneer,
Polyester
Enterprise,
Specialty
Fibers
and
Specialty
Polymers.
The
Company's
non-aligned
businesses
and
embryonic
businesses
are
grouped
under
Other. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | E.I.
DuPont
de
Nemours
and
Company
is
a
global
science
and
technology
company
with
operations
in
high-performance
materials,
specialty
chemicals,
pharmaceuticals
and
biotechnology.
For
the
six
months
ended
6/30/01,
total
revenues
decreased
11%
to
$14.24
billion.
Net
income
applicable
to
Common
before
accounting
change
fell
82%
to
$266
million.
Results
reflect
lower
volumes
due
to
economic
weakness
and
$1.05
billion
in
write-downs
and
other
charges. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Charles Holliday, Jr., 53 Chairman
and CEO | $2.8M | -- | Gary Pfeiffer, 51 CFO,
Sr. VP | 1.3M | -- | Richard Goodmanson, 53 COO,
Exec. VP | 1.5M | -- | Stacey Mobley, 55 Sr.
VP, CAO, Gen. Counsel | 870K | $559K | Thomas Connelly, Jr., 48 Sr.
VP, Chief Science and Technology Officer | -- | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|